ePrints

Perspective of Cyclin-dependent kinase 9 (CDK9) as a Drug Target

Lookup NU author(s): Dr Sonja Baumli

Downloads

Full text for this publication is not currently held within this repository. Alternative links are provided below where available.

Abstract

Deregulation of cyclin-dependent kinases (CDKs) has been associated with many cancer types and has evoked an interest in chemical inhibitors with possible therapeutic benefit. While most known inhibitors display broad selectivity towards multiple CDKs, recent work highlights CDK9 as the critical target responsible for the anticancer activity of clinically evaluated drugs. In this review, we discuss recent findings provided by structural biologists that may allow further development of highly specific inhibitors of CDK9 towards applications in cancer therapy. We also highlight the role of CDK9 in inflammatory processes and diseases.

Publication metadata

Author(s): Krystof V, Baumli S, Furst R

Publication type: Review

Publication status: Published

Journal: Current Pharmaceutical Design

Year: 2012

Volume: 18

Issue: 20

Pages: 2883-2890

Print publication date: 01/07/2012

ISSN (print): 1381-6128

ISSN (electronic): 1873-4286

Publisher: BENTHAM SCIENCE PUBL LTD

URL: http://dx.doi.org/10.2174/138161212800672750

DOI: 10.2174/138161212800672750

Share